Astel­las, Sony part­ner up for an­ti­body-drug con­ju­gate plat­form to cre­ate 'bet­ter per­form­ing' drugs

Astel­las and Sony Cor­po­ra­tion have teamed up to de­vel­op a new an­ti­body-drug con­ju­gate plat­form that de­liv­ers drugs to the tar­get cells in a bid to de­vel­op “bet­ter per­form­ing” AD­Cs, Astel­las an­nounced Tues­day.

The two com­pa­nies have been in talks to de­vel­op the plat­form since Ju­ly 2022, and have al­ready done fea­si­bil­i­ty stud­ies us­ing hu­man can­cer cells. In the project, the com­pa­nies will use Sony’s poly­mer­ic ma­te­r­i­al, called Ki­ravia Back­bone, as the “link­er” be­tween AD­Cs and the tar­get cells.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN